KBTBD3 Inhibitors
KBTBD3 inhibitors encompass a range of chemical compounds that indirectly inhibit the functional activity of the KBTBD3 protein. Thapsigargin, by disrupting calcium homeostasis within the endoplasmic reticulum, induces ER stress and the unfolded protein response, which can target KBTBD3 for degradation. Similarly, MG-132's inhibition of proteasomal activity leads to an accumulation of misfolded proteins, which may include KBTBD3, hindering its proper function. Brefeldin A and Tunicamycin interfere with protein processing and trafficking, potentially causing mislocalization and misfolding of KBTBD3, respectively. Cycloheximide and Rapamycin reduce the synthesis of KBTBD3 by inhibiting protein biosynthesis and mTOR signaling. Mitomycin C and Chloroquine, through mechanisms involving cell cycle arrestand lysosome function, respectively, can prevent the necessary cellular conditions required for KBTBD3's activity. Lithium chloride and Salubrinal modulate the phosphorylation state of proteins, which may affect the stability and turnover of KBTBD3.
Chemical compounds like 2-Deoxy-D-glucose exert metabolic stress, potentially reducing the energy-dependent processes essential for KBTBD3's function. Trichostatin A, by altering gene expression, may decrease the production of proteins that assist in the folding and function of KBTBD3. These compounds, through their diverse actions on cellular pathways and processes, cumulatively contribute to the functional inhibition of KBTBD3.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
A sesquiterpene lactone that inhibits the sarco/endoplasmic reticulum Ca2+ ATPase (SERCA), leading to the depletion of calcium stores within the endoplasmic reticulum (ER). The resulting ER stress can inhibit KBTBD3 by inducing the unfolded protein response (UPR), which can lead to the degradation of misfolded proteins including KBTBD3. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
A proteasome inhibitor that prevents the degradation of ubiquitinated proteins, which can lead to an accumulation of misfolded or damaged proteins. This proteostatic stress can indirectly inhibit KBTBD3 by overwhelming the protein quality control mechanisms, potentially leading to the misfolding or aggregation of KBTBD3. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $30.00 $52.00 $122.00 $367.00 | 25 | |
An inhibitor of ADP-ribosylation factor (ARF), which leads to the disassembly of the Golgi apparatus. This disruption can affect the post-translational modification and proper trafficking of proteins, including KBTBD3, leading to its functional inhibition due to mislocalization. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $169.00 $299.00 | 66 | |
An N-glycosylation inhibitor that blocks the addition of N-linked glycosylation on nascent proteins, which can lead to ER stress and the UPR. The UPR may subsequently reduce the folding capacity for proteins like KBTBD3, leading to its functional inhibition. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $40.00 $82.00 $256.00 | 127 | |
An inhibitor of eukaryotic protein biosynthesis by interfering with the translocation step in protein synthesis, which can lead to the inhibition of KBTBD3 by limiting its synthesis and availability in the cell. | ||||||
Mitomycin C | 50-07-7 | sc-3514A sc-3514 sc-3514B | 2 mg 5 mg 10 mg | $65.00 $99.00 $140.00 | 85 | |
An alkylating agent that can induce DNA damage and lead to cell cycle arrest. This inhibition of cell proliferation can indirectly inhibit KBTBD3 by preventing the cell cycle-dependent expression or activation of proteins, including KBTBD3. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $68.00 | 2 | |
A known autophagy inhibitor that raises the pH of lysosomes, leading to impaired degradation processes within the cell. The reduction in autophagic flux can indirectly inhibit KBTBD3 by disrupting the cellular degradation pathways that may be necessary for its turnover and function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor that suppresses protein synthesis and cell growth. The inhibition of mTOR signaling can indirectly inhibit KBTBD3 by reducing the overall protein synthesis rate, thereby decreasing the synthesis of KBTBD3. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
An inhibitor of glycogen synthase kinase-3 (GSK-3), which can lead to the stabilization of proteins targeted for degradation. The inhibition of GSK-3 can indirectly inhibit KBTBD3 by potentially altering its phosphorylation state and stability. | ||||||
2-Deoxy-D-glucose | 154-17-6 | sc-202010 sc-202010A | 1 g 5 g | $65.00 $210.00 | 26 | |
A glycolysis inhibitor that mimics glucose but cannot be fully utilized in glycolysis, leading to cellular energy stress. This can indirectly inhibit KBTBD3 by limiting the energy-dependent processes required for its function. | ||||||